在2024美国肝病研究协会（AASLD）肝脏大会上公布的2期临床试验结果显示，brelovitug在所有剂量组中均实现了100%的病毒学缓解，并且多达78%的参与者达到了病毒学缓解和丙氨酸氨基转移酶（ALT）水平正常化的复合终点。所有剂量组中均观察到丁型肝炎病毒水平和ALT水平的平行下降，这表明通过降低病毒载量对肝脏炎症具有有益效果。

Despite numerous treatment advances ... and hepatitis B s antigen (HBsAg), which is HBV’s envelope protein. In addition to the excess HBsAg present in circulating virions, large amounts of ...

Researchers update clinical practice guidelines for how to prevent and monitor hepatitis B virus reactivation.

Treatment with xalnesiran, a small interfering RNA molecule, plus an immunomodulator resulted in hepatitis B surface antigen loss among adults with chronic HBV infection, according to a study ...

The primary efficacy end point was HBsAg loss at 24 weeks after the end of treatment. The researchers found that a primary end point event occurred in 7, 3, 12, 23, and 0 percent of patients in ...

Discover a clinical trial that was conducted to evaluate the efficacy and safety of autologous HBV vaccine-pulsed dendritic cells and their induced T cells.

Brelovitug is designed to neutralize and remove hepatitis B and hepatitis D virions and deplete HBsAg-containing subviral particles, which makes brelovitug a potentially safe and highly efficacious ...

The Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to brelovitug (BJT-778) for the treatment of chronic hepatitis delta (CHD).

The US Food and Drug Administration (FDA) has granted breakthrough therapy designation to Bluejay Therapeutics’ fully human immunoglobulin G1 (IgG1) monoclonal antibody, brelovitug, to treat chronic ...

At 72 weeks, IHCs in the treatment group were categorized into an HBsAg clearance group and an HBsAg persistence group. Differences in T lymphocyte subsets among these groups were compared ...

The most recent results also demonstrated durable HBsAg declines across all treatment groups, consistent with data previously presented at the European Association for the Study of the Liver (EASL ...